Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of hematologic malignancies. CC-486 administered for 7 days per 28-day treatment cycle was evaluated in a phase 1 dose-finding study. AZA has a short...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4832070/
https://ncbi.nlm.nih.gov/pubmed/26442612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados